{"schema":"hottub-news/story/v1","story":"st_7yv6sclcqptq27my3xvq","title":"FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/fda-flagged-glp-1-vision-loss-signal-in-2025-but-u-s-ozempic-and-7yv6sclcqp","count":1,"items":[{"id":"n_7yv6sclcqptq27my3xvq","seq":582932,"kind":"article","title":"FDA Flagged GLP-1 Vision Loss Signal in 2025, but U.S. Ozempic and Mounjaro Labels Still Lack NAION Warning","url":"https://www.medicaldaily.com/fda-glp1-naion-signal-us-label-warning-review-479225","summary":"FDA listed NAION as a possible GLP-1 safety signal in March 2025, yet U.S. labels still lack a warning, while Europe, the UK, and Australia have acted.","published":"2026-09-29T04:31:13Z","seen":"2026-09-29T05:12:27Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q47521958","name":"Ozempic","type":"other"},{"id":"Q108324770","name":"tirzepatide","type":"other"}],"mentions":2,"story":"st_7yv6sclcqptq27my3xvq","category":"economy-business","category_p":0.33000001311302185,"category2":"health","sentiment":"neutral","tone":-0.25,"political":0.17000000178813934}]}